Research Article 
Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists
Michael H. Davidson, Christie M. Ballantyne, Terry A. Jacobson, Vera A. Bittner, Lynne T. Braun, Alan S. Brown, W. Virgil Brown, William C. Cromwell, Ronald B. Goldberg, James M. McKenney, Alan T. Remaley, Allan D. Sniderman, Peter P. Toth, Sotirios Tsimikas, Paul E. Ziajka, Kevin C. Maki and Mary R. Dicklin
Journal of Clinical Lipidology, 2011, 5(5), 338-367. DOI: 10.1016/j.jacl.2011.07.005
Abstract
The National Cholesterol Education Program Adult Treatment Panel guidelines have established low-density lipoprotein cholesterol (LDL-C) treatment goals, and secondary non-high-density lipoprotein (HDL)-C treatment goals for persons with hypertriglyceridemia. The use of lipid-lowering therapies, particularly statins, to achieve these goals has reduced cardiovascular disease (CVD) morbidity and mortality; however, significant residual risk for events remains. This, combined with the rising prevalence of obesity, which has shifted the risk profile of the population toward patients in whom LDL-C is less predictive of CVD events (metabolic syndrome, low HDL-C, elevated triglycerides), has increased interest in the clinical use of inflammatory and lipid biomarker assessments. Furthermore, the cost effectiveness of pharmacological intervention for both the initiation of therapy and the intensification of therapy has been enhanced by the availability of a variety of generic statins. This report describes the consensus view of an expert panel convened by the National Lipid Association to evaluate the use of selected biomarkers [C-reactive protein, lipoprotein-associated phospholipase A2, apolipoprotein B, LDL particle concentration, lipoprotein(a), and LDL and HDL subfractions] to improve risk assessment, or to adjust therapy. These panel recommendations are intended to provide practical advice to clinicians who wrestle with the challenges of identifying the patients who are most likely to benefit from therapy, or intensification of therapy, to provide the optimum protection from CV risk.
ASCI-ID: 2746-217
Similar Articles
Non-HDL-cholesterol/apolipoprotein B ratio: A useful distinguishing feature in the screening for type III hyperlipoproteinemia
Journal of Clinical Lipidology, 2010, 4(2), 99-104. DOI: 10.1016/j.jacl.2010.01.004
NLA Symposium screening and treatment of familial hypercholesterolemia: How can we do better? Opening and introductionsJournal of Clinical Lipidology, 2010, 4(5), 335-337. DOI: 10.1016/j.jacl.2010.08.016
Novel therapies and new targets of treatment for familial hypercholesterolemiaJournal of Clinical Lipidology, 2010, 4(5), 350-356. DOI: 10.1016/j.jacl.2010.08.015
Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurementJournal of Clinical Lipidology, 2011, 5(4), 264-272. DOI: 10.1016/j.jacl.2011.05.004
Novel missense variants in LCAT and APOB genes in an Italian kindred with familial lecithin:cholesterol acyltransferase deficiency and hypobetalipoproteinemiaJournal of Clinical Lipidology, 2012, 6(3), 244-250. DOI: 10.1016/j.jacl.2012.01.006
Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)Journal of Clinical Lipidology, 2012, 6(6), 565-572. DOI: 10.1016/j.jacl.2012.07.001
Common variation in Cholesteryl Ester Transfer Protein: Relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratioJournal of Clinical Lipidology, 2013, 7(1), 56-64. DOI: 10.1016/j.jacl.2012.05.003
JCL Roundtable: Drug treatment of severe forms of familial hypercholesterolemiaJournal of Clinical Lipidology, 2014, 8(1), 10-17. DOI: 10.1016/j.jacl.2013.09.004
Clinical perspective: Have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidologyJournal of Clinical Lipidology, 2011, 5(3), 124-132. DOI: 10.1016/j.jacl.2011.02.006
Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥2 mg/L)Journal of Clinical Lipidology, 2011, 5(5), 401-407. DOI: 10.1016/j.jacl.2011.06.010
Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery diseaseJournal of Clinical Lipidology, 2014, 8(5), 494-500. DOI: 10.1016/j.jacl.2014.07.001
Evidence of dependence of lipoprotein(a) on triglyceride and high-density lipoprotein metabolismJournal of Clinical Lipidology, 2012, 6(1), 27-32. DOI: 10.1016/j.jacl.2011.08.004
Low-density lipoprotein apheresis is effective in reducing lipoprotein(a) levels and in improving symptoms in a patient with refractory angina secondary to accelerated coronary artery diseaseJournal of Clinical Lipidology, 2012, 6(2), 192-194. DOI: 10.1016/j.jacl.2011.11.003
Lipoprotein(a) particle concentration and lipoprotein(a) cholesterol assays yield discordant classification of patients into four physiologically discrete groupsJournal of Clinical Lipidology, 2012, 6(4), 368-373. DOI: 10.1016/j.jacl.2012.01.004
Significant reduction of elevated serum lipoprotein(a) concentrations during levo-thyroxine-replacement therapy in a hypothyroid patientJournal of Clinical Lipidology, 2012, 6(4), 388-391. DOI: 10.1016/j.jacl.2012.01.007
Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemiaJournal of Clinical Lipidology, 2011, 5(6), 483-492. DOI: 10.1016/j.jacl.2011.09.001